Identification
NameLucinactant
Accession NumberDB04897
TypeBiotech
GroupsApproved
Description

Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). More specifically, it mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components. FDA approved on March 6, 2012.

Protein structureNo structure small
Related Articles
Protein chemical formulaC 126 H 238 N 26 O 22
Protein average weight2470.2 Da
Sequences
>Protein sequence for sinapultide
KLLLLKLLLLKLLLLKLLLLK
Download FASTA Format
Synonyms
ATI-02
KL4-surfactant
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIINot Available
CAS number825600-90-6
Pharmacology
Indication

Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

Structured Indications Not Available
Pharmacodynamics

Lucinactant is a new synthetic surfactant containing a protein that mimics human surfactant protein-B, is effective at preventing respiratory distress syndrome (RDS) and related complications in preterm infants. Lucinactant has been shown to have antiinflammatory properties, is resistant to proteolytic degradation and oxidation, and has no potential for transmitting animal-derived diseases. Lucinactant has proven safe and effective in the prevention of RDS in preterm infants and as a treatment for MAS in full-term infants and for adult ARDS.

Mechanism of action

Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).

Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
Toxicity

Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololAcebutolol may increase the bradycardic activities of Lucinactant.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Lucinactant.Approved, Investigational
AtenololAtenolol may increase the bradycardic activities of Lucinactant.Approved
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Lucinactant.Approved
BeractantLucinactant may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the bradycardic activities of Lucinactant.Approved
BisoprololBisoprolol may increase the bradycardic activities of Lucinactant.Approved
BretyliumBretylium may increase the bradycardic activities of Lucinactant.Approved
CalfactantLucinactant may increase the bradycardic activities of Calfactant.Approved
CarteololCarteolol may increase the bradycardic activities of Lucinactant.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Lucinactant.Approved, Investigational
CeritinibLucinactant may increase the bradycardic activities of Ceritinib.Approved
ClonidineClonidine may increase the bradycardic activities of Lucinactant.Approved
CrizotinibLucinactant may increase the bradycardic activities of Crizotinib.Approved
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Lucinactant.Approved, Vet Approved
DigoxinDigoxin may increase the bradycardic activities of Lucinactant.Approved
DiltiazemDiltiazem may increase the bradycardic activities of Lucinactant.Approved
DonepezilDonepezil may increase the bradycardic activities of Lucinactant.Approved
DronedaroneDronedarone may increase the bradycardic activities of Lucinactant.Approved
EsmololEsmolol may increase the bradycardic activities of Lucinactant.Approved
FingolimodLucinactant may increase the bradycardic activities of Fingolimod.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Lucinactant.Approved
GuanfacineGuanfacine may increase the bradycardic activities of Lucinactant.Approved, Investigational
IvabradineLucinactant may increase the bradycardic activities of Ivabradine.Approved
LabetalolLabetalol may increase the bradycardic activities of Lucinactant.Approved
LacosamideLucinactant may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideLucinactant may increase the bradycardic activities of Lanreotide.Approved
LevobunololLevobunolol may increase the bradycardic activities of Lucinactant.Approved
MethyldopaMethyldopa may increase the bradycardic activities of Lucinactant.Approved
MetipranololMetipranolol may increase the bradycardic activities of Lucinactant.Approved
MetoprololMetoprolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
NadololNadolol may increase the bradycardic activities of Lucinactant.Approved
NebivololNebivolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
OctreotideOctreotide may increase the bradycardic activities of Lucinactant.Approved, Investigational
PasireotideLucinactant may increase the bradycardic activities of Pasireotide.Approved
PenbutololPenbutolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
PindololPindolol may increase the bradycardic activities of Lucinactant.Approved
Poractant alfaLucinactant may increase the bradycardic activities of Poractant alfa.Approved
PropafenonePropafenone may increase the bradycardic activities of Lucinactant.Approved
PropranololPropranolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Lucinactant.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Lucinactant.Approved
SotalolSotalol may increase the bradycardic activities of Lucinactant.Approved
SufentanilSufentanil may increase the bradycardic activities of Lucinactant.Approved, Investigational
TimololTimolol may increase the bradycardic activities of Lucinactant.Approved
TizanidineTizanidine may increase the bradycardic activities of Lucinactant.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Lucinactant.Approved, Investigational
VerapamilVerapamil may increase the bradycardic activities of Lucinactant.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005 Apr;115(4):1030-8. [PubMed:15805381 ]
  2. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C, Mazela J, Liu G: One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics. 2007 Jun;119(6):e1361-70. Epub 2007 May 28. [PubMed:17533176 ]
  3. Halliday HL, Speer CP: Lucinactant versus poractant-alpha in premature lambs. Pediatrics. 2006 Jun;117(6):2324-5; author reply 2325. [PubMed:16740886 ]
  4. Gastiasoro-Cuesta E, Alvarez-Diaz FJ, Rey-Santano C, Arnaiz-Renedo A, Loureiro-Gonzalez B, Valls-i-Soler A: Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome. Pediatrics. 2006 Feb;117(2):295-303. [PubMed:16452346 ]
  5. Donn SM: Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Expert Opin Investig Drugs. 2005 Mar;14(3):329-34. [PubMed:15833063 ]
  6. Moen MD, Perry CM, Wellington K: Lucinactant: in neonatal respiratory distress syndrome. Treat Respir Med. 2005;4(2):139-45; discussion 146-7. [PubMed:15813666 ]
  7. Doyle I: Lucinactant (Discovery Laboratories). IDrugs. 2002 Jul;5(7):696-702. [PubMed:12802703 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 48:36
PDB EntriesNot Available
FDA labelDownload (267 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Hypoxemic Respiratory Failure1
2RecruitingTreatmentRespiratory Distress Syndrome (RDS)1
2TerminatedPreventionChronic Lung Disease of Prematurity / Premature Births / Respiratory Distress Syndrome, Newborn1
2TerminatedTreatmentAcute Respiratory Distress Syndrome (ARDS)1
3TerminatedTreatmentMeconium Aspiration Syndrome1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5407914 No2012-03-062013-11-17Us
Properties
StateLiquid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24